Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03660241 · ClinicalTrials.gov registry record · Phase 1
A Renal Impairment Study for PF-04965842
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT03660241 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 23 participants.
The verdict
NCT03660241, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This study is a phase 1 non-randomized, open-label, single-dose, parallel-group study of PF 04965842 in subjects with severe renal impairment and subjects without renal impairment (Part 1) and in subjects with moderate renal impairment (Part 2).
Interventions
- DRUG PF-04965842
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2018-10-05 |
| Est. Completion | 2019-11-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03660241
The ClinicalTrials.gov registry entry for NCT03660241 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-04965842 is the first listed.
NCT03660241 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03660241 about?
NCT03660241 is a clinical study titled "A Renal Impairment Study for PF-04965842". This study is a phase 1 non-randomized, open-label, single-dose, parallel-group study of PF 04965842 in subjects with severe renal impairment and subjects without renal impairment (Part 1) and in subjects with moderate renal impairment (Part 2).
What is the current status of trial NCT03660241?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2018-10-05. Estimated completion is 2019-11-05.
What interventions are being tested in trial NCT03660241?
The interventions under investigation include: PF-04965842 (DRUG).
Who is sponsoring clinical trial NCT03660241?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.